Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
Condition(s):Advanced or Metastatic Solid Tumors; FGFR Mutations; FGFR TranslocationsLast Updated:May 10, 2022Terminated
Hide Studies Not Open or Pending
Condition(s):Advanced or Metastatic Solid Tumors; FGFR Mutations; FGFR TranslocationsLast Updated:May 10, 2022Terminated
Condition(s):Solid Tumor MalignancyLast Updated:March 20, 2023Terminated
Condition(s):Solid Tumor; FGF Receptor Gene Mutation; FGF Amplification; FGF Receptor Gene Family Rearrangement; FGF Receptor Gene TranslocationLast Updated:September 1, 2023Recruiting
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene MutationLast Updated:April 3, 2023Terminated
Condition(s):Lung Cancer; NSCLC; Pulmonary Neoplasm; Squamous Cell Lung Cancer; NSCLC Stage IVLast Updated:June 9, 2023Terminated
Condition(s):Solid TumorLast Updated:June 5, 2023Completed
Condition(s):CholangiocarcinomaLast Updated:February 23, 2023Completed
Condition(s):Multiple MyelomaLast Updated:December 3, 2019Completed
Condition(s):Intrahepatic Cholangiocarcinoma; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene TranslocationLast Updated:August 28, 2023Recruiting
Condition(s):Tumor Pathway Activations Inhibited by DovitinibLast Updated:March 20, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.